<DOC>
	<DOCNO>NCT02174562</DOCNO>
	<brief_summary>This research aim help older African Americans diabetes mild memory problem improve take medication control diabetes . This may preserve independence health , prevent cognitive functional decline , reduce health care cost . As population age become racially diverse , find way achieve outcomes great public health importance .</brief_summary>
	<brief_title>Improving Medication Adherence Older African Americans With Diabetes</brief_title>
	<detailed_description>The prevalence type 2 diabetes ( DM ) old person increase rapidly . DM increase risk Mild Cognitive Impairment ( MCI ) , transition state normal cognition dementia often characterized memory executive function deficit . These deficit reduce adherence DM medication , worsens glycemic control increase risk adverse DM-related health outcome . Improving medication adherence may prevent outcomes reduce health care cost . This important old person DM particularly old African Americans ( AAs ) . They twice rate DM , worse cognitive function , low medication adherence , bad glycemic control white . One million old AAs DM number double 2030 . Because 30 % also MCI , low medication adherence important problem . This necessitate culturally relevant intervention compensate cognitive deficit improve medication adherence glycemic control . We propose randomize controlled clinical trial test efficacy collaborative Primary Care-Occupational Therapy ( PC-OT ) intervention lower hemoglobin A1c ( HbA1c ) level older AAs DM , MCI , HbA1c ≥ 7.5 % , ≤ 80 % adherence oral hypoglycemic medication . PC-OT consists : 1 ) primary care physician ( PCP ) - occupational therapist ( OT ) collaboration ; 2 ) DM education tailor cognitive impairment ; 3 ) in-home OT cognitive-functional assessment ; 4 ) OT-delivered Behavior Activation increase adherence medication diabetes self-management ( DSM ) practice ( e.g. , diet ) . We recruit 100 participant primary care clinic randomize PC-OT Enhanced Usual Care ( EUC ) . EUC usual medical care plus low intensity DM education deliver community health worker . Participants PC-OT EUC 6 initial in-home treatment session 3 month , 3 booster session 12 month study . The primary outcome reduction HbA1c 0.5 % , reduce risk adverse medical event . The primary efficacy analysis compare proportion participant PC-OT EUC achieve outcome month 6 ( short term effect ) month 12 ( maintenance effect ) . We measure medication adherence use electronic Medication Event Monitoring System , prescription refill , self-reports . A secondary aim determines improve medication adherence mediate PC-OT 's impact HbA1c level . We also evaluate PC-OT 's effect DSM practice ; ER visit hospitalization ; cognition ; function ; mood ; quality life ; PC-OT 's cost net financial benefit . This first study determine PCPs , collaborate OTs ( expert develop strategy compensate cognitive/physical deficit ) , improve medication adherence glycemic control , prevent cognitive functional decline old person DM MCI . If PC-OT effective high risk population old AAs , benefit may extend old person DM enormous public health significance .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>1 . Age 65 year old . 2 . Selfidentified African American , black , black American , black/Caribbean . 3 . Type II DM ( i.e. , physician diagnosis medication treatment ) . 4 . HbA1c level ≥ 7.5 % . 5 . MCI , base National Institute Aging/Alzheimer 's Association ( NIA/AA ) criterion . 6 . ≤ 80 % adherence oral hypoglycemic medication , document runin phase use Medication Event Monitoring System ( MEMS ) . 1 . Dementia , base National Institute Aging/Alzheimer 's Association criterion . 2 . Treatment insulin injectable . 3 . DSMV psychiatric disorder depressive disorder . 4 . Endstage renal disease require dialysis . 5 . Hearing/Vision ( i.e. , severe diabetic retinopathy ) motor ( e.g. , peripheral neuropathy ) impairment precludes research participation .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
</DOC>